SCHEMBL13503573

SCHEMBL13503573

CC(C)C1CCC(=Cc2ccccc2F)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.46
KMT2A Q03164 2/20 0.39
IGF1R P08069 1/20 0.39
NFE2L2 Q16236 5/20 0.38
IKBKB O14920 2/20 0.38
RAF1 P04049 1/20 0.38
RPS6KB1 P23443 1/20 0.38
MAPK1 P28482 1/20 0.38
AKT1 P31749 1/20 0.38
AKT2 P31751 1/20 0.38
KDR P35968 1/20 0.38
PRKAG1 P54619 1/20 0.38
MAP2K1 Q02750 1/20 0.38
PRKAA1 Q13131 1/20 0.38
MAPK14 Q16539 1/20 0.38
DYRK2 Q92630 1/20 0.38
NEK1 Q96PY6 1/20 0.38
PRKAB1 Q9Y478 1/20 0.38
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13503566 0.88 MAPT (0.35) MAPTOPRL1
SCHEMBL13503641 0.82 IKBKB (0.37) MAPTNFE2L2IKBKBOPRL1
SCHEMBL13504005 0.81 MAPT (0.45) MAPTKMT2AIGF1RNFE2L2IKBKB
SCHEMBL13504064 0.81 NFE2L2 (0.37) MAPTNFE2L2OPRL1SRD5A2
SCHEMBL13503716 0.81 SRD5A2 (0.38) NFE2L2OPRL1SRD5A2
SCHEMBL13503572 0.81 MAPT (0.46) MAPTKMT2ADYRK2MEN1NPC1
SCHEMBL14409763 0.81 OPRM1 (0.31) OPRL1
SCHEMBL13503567 0.81 HSD11B1 (0.44) MAPTKMT2AIKBKBDYRK2MEN1
SCHEMBL17684676 0.80 IKBKB (0.45) MAPTKMT2AIGF1RNFE2L2IKBKB
SCHEMBL13503594 0.79 SRD5A2 (0.32) SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-7449485-B2 N-sulfonylurea apoptosis promoters ABBOTT LABORATORIES INC. (US) 2008-11-11 US disclosed
US-7449485-B2 N-sulfonylurea apoptosis promoters ABBOTT LABORATORIES INC. (US) 2008-11-11 US disclosed
US-20080146572-A1 N-SULFONYLUREA APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2008-06-19 US disclosed
US-20080146572-A1 N-SULFONYLUREA APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2008-06-19 US disclosed
US-7358251-B2 N-sulfonylurea apoptosis promoters ABBOTT LABORATORIES (US) 2008-04-15 US disclosed
US-7358251-B2 N-sulfonylurea apoptosis promoters ABBOTT LABORATORIES (US) 2008-04-15 US disclosed
EP-1487811-B1 N-SULFONYLUREA APOPTOSIS PROMOTERS ABBOTT LAB (US) 2007-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146572-A1 N-SULFONYLUREA APOPTOSIS PROMOTERS BAX, BCL2, BAD MAPT 4694/4885KMT2A 3213/4885IGF1R 1398/4885
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BAD MAPT 4433/4885KMT2A 1794/4885IGF1R 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.